Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy ALL the following criteria at study entry:~* Subjects for whom the investigator believes that the parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol .~* A male or female child 3 to 17 years of age inclusive, at the time of the first vaccination.~* Written informed consent obtained from the subject's parent or guardian. Assent obtained from the subject when applicable.~* Good general health as established by medical history and clinical examination before entering into the study.~* Comprehension by the subject's parent or guardian of the study requirements, ability to comprehend and comply with procedures for collection of short- and long-term safety data, expressed availability for the required study period, and ability and willingness to attend scheduled visits.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device (i.e., a common-use phone serving multiple rooms or apartments).~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:~* Child in care~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Planned administration of any vaccine 30 days prior and 21 days after any study vaccine administration.~* Active participation in other clinical trials.~* Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are allowed.~* Acute disease and/or fever at the time of enrolment:~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required).~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine.~* Receipt of any immunoglobulins and/or any blood products within 9 months of study enrolment or planned administration of any of these products during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to vaccine components or a history of severe adverse reaction to a previous influenza vaccine.~* History of seizures or progressive neurological disease.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* Diagnosed with cancer or any chronic severe disease.~* Previous administration of any H5N1 vaccine.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group (Type: EXPERIMENTAL): Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
- GSK1562902A Formulation 1 - Havrix / Havrix Jr Group (Type: EXPERIMENTAL): Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
- GSK1562902A Formulation 2 - Havrix / Havrix Jr Group (Type: ACTIVE_COMPARATOR): Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
- Havrix / Havrix Jr Group (Type: ACTIVE_COMPARATOR): Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete